GlassScriptPhysician profile
Christopher P Kampas
NPI 1154369536
$1,658.34
in general payments reported to CMS, 2019-2025
24 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $171 · 2021: $32.25 · 2022: $52.57 · 2023: $173 · 2024: $289 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $341.69 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $183.49 | 2019-2021 | |
| Novo Nordisk INC | $136.86 | 2019-2024 | Wegovy |
| Abbott Laboratories | $128.95 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $117.37 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $84.98 | 2019-2024 | |
| Exact Sciences Corporation | $82.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $80.76 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Genentech USA, INC. | $64.51 | 2019-2020 | |
| Corcept Therapeutics | $48.88 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $46.30 | 2019-2020 | |
| Sanofi Pasteur INC. | $45.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $41.86 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Pfizer INC. | $40.00 | 2025 | |
| Dexcom, INC. | $37.49 | 2023 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.47 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $25.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.05 | 2024 | |
| Allergan, INC. | $20.43 | 2020 | |
| Astellas Pharma US INC | $18.16 | 2019 | |
| Abbvie INC. | $17.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2019 | |
| Amgen INC. | $15.79 | 2019 | |
| Dynavax Technologies Corporation | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kampas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.